Bioxodes

Rue Santos-Dumont, 1
6041 GOSSELIES
Belgium

[email protected] +32 71 23 96 00 bioxodes.com

Type
- Company
Application domains
- Biopharma
Core business
- R&D
Technology
- Biologics
- Small molecule
Therapeutic area
- Neurology

Bioxodes is a clinical stage company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in haemorrhagic stroke patients.

Related news

News

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

All member's news